Abstract:Artemisinin (ARS) and its derivatives, which are clinically used antimalarial agents, have shown antitumor activities. Their therapeutic potencies, however, are limited by their low solubility and poor bioavailability. Here, through a pharmacophore hybridization strategy, we synthesized ARS-drug conjugates, in which the marketed chemotherapeutic agents chlorambucil, melphalan, flutamide, aminoglutethimide, and doxifluridine, were separately bonded to Dihydroartemisinin (DHA) through various linkages. Of these, the artemisinin-melphalan conjugate, ARS4, exhibited most toxicity to human ovarian cancer cells but had low cytotoxicity to normal cells. ARS4 inhibited the growth and proliferation of ovarian cancer cells and resulted in S-phase arrest, apoptosis, and inhibition of migration; these effects were stronger than those of its parent drugs, DHA and melphalan. Furthermore, ARS4 modulated the expression of proteins involved in cell cycle progression, apoptosis, and the epithelialmesenchymal transition (EMT). Moreover, in mice, ARS4 inhibited growth and intraperitoneal dissemination and metastasis of ovarian cancer cells without observable toxic effects. Our results provide a basis for development of the compound as a chemotherapeutic agent.Research in context: Artemisinin compounds have recently received attention as anticancer agents because of their clinical safety profiles and broad efficacy. However, their therapeutic potencies are limited by low solubility and poor bioavailability. Here, we report that ARS4, an artemisinin-melphalan conjugate, possesses marked invitro and in-vivo antitumor activity against ovarian cancer, the effects of which are stronger than those for its parent drugs, Dihydroartemisinin and melphalan. In mice, ARS4 inhibits localized growth of ovarian cancer cells and intraperitoneal dissemination and metastasis without appreciable host toxicity. Thus, for patients with ovarian cancer, ARS4 is a promising chemotherapeutic agent.(C) 2016 The Authors. Published by Elsevier B.V.

Therapeutic Potentials and Mechanisms of Artemisinin and its Derivatives for Tumorigenesis and Metastasis.

Anti-malarial drug: the emerging role of artemisinin and its derivatives in liver disease treatment

Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug

Artemisinin and Its Derivatives as a Repurposing Anticancer Agent: What Else Do We Need to Do?

Repurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge?

Artemisinin and Its Derivatives as Potential Anticancer Agents

Mechanisms and Molecular Targets of Artemisinin in Cancer Treatment

Design of novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties

Research Advance in Antitumor Activities of Artemisinin and Its Derivatives

Structural optimization and biological evaluation for novel artemisinin derivatives against liver and ovarian cancers

Targeting Autophagy Enhances the Anticancer Effect of Artemisinin and Its Derivatives

Research Progress on Pharmacological Activities of Artemisinin and Its Derivatives

Preclinical Efficacy and Safety Assessment of Artemisinin-Chemotherapeutic Agent Conjugates for Ovarian Cancer

The Potential Mechanisms by which Artemisinin and Its Derivatives Induce Ferroptosis in the Treatment of Cancer

Chemical Constituents and Antitumor Mechanisms of Artemisia

Artemisinin Rewires the Protein Interaction Network in Cancer Cells: Network Analysis, Pathway Identification, and Target Prediction

Research Progress on Artemisinin and Its Derivatives Against Hematological Malignancies

Artemisinin-Type Drugs in Tumor Cell Death: Mechanisms, Combination Treatment with Biologics and Nanoparticle Delivery

Biological Activities of Artemisinin Derivatives Beyond Malaria.

Anti-tumor Mechanism of Artesunate

Synthesis and Anti-Tumor Effect of Artemisone Derivatives